Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Neuropilin-1


Brief Information

Target Synonym:BDCA4,NP1,Neuropilin-1,NRP1,CD304,VEGF165R,Neuropilin 1,Vascular Endothelial Cell Growth Factor 165 Receptor,NRP,Transmembrane Receptor,CD304 Antigen
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 Neuropilin-1 SPR

Human NRP1, Fc Tag (Cat. No. NR1-H5252) captured on Protein A Chip can bind Human VEGF-B, His Tag (Cat. No. VE6-H5225) with an affinity constant of 23.8 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

 Neuropilin-1 BLI

Loaded Biotinylated Human Neuropilin-1, His,Avitag (Cat. No. NR1-H82E3) on SA Biosensor, can bind SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H3) with an affinity constant of 0.663 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Neuropilin-1 (NRP1) is also known as Vascular endothelial cell growth factor 165 receptor (VEGF165R), CD antigen CD304, which belongs to the neuropilin family. The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Certepetide CEND-1; iRGD; CIND-1; LSTA1; QLC12102; LSTA-1 Phase 2 Clinical Drugcendr Inc Oropharyngeal Neoplasms; Neoplasm Metastasis; Carcinoma, Squamous Cell; Mouth Neoplasms; Laryngeal Neoplasms; Gallbladder Neoplasms; Carcinoma, Pancreatic Ductal; Appendiceal Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Head and Neck Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Pancreatic Neoplasms; Hypopharyngeal Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message